-
Content Validation of the Most Bothersome Symptom - Essential Tremor Questionnaire (MBS-ET): A Cognitive Debriefing Study
Mar 10, 2025, 14:00 PM -
Budget Impact Analysis of Venetoclax Combination Therapies for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Aged 75 Years or Older, or Who Have Comorbidities That Preclude Use of Intensive Induction Chemotherapy
Mar 10, 2025, 14:00 PM -
Racial and Ethnic Disparities in Orphan Drug Utilization Among Medicare Beneficiaries
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization Costs in People With Cognitive Impairment Associated With Schizophrenia: A US Non-Interventional Cohort Study of Real World Data
Mar 10, 2025, 14:00 PM -
A Standardized Framework for the Acceptance of Non-Randomized Evidence From Real-World Data in HTA: Insights From EU Guidelines and National Practices
Mar 10, 2025, 14:00 PM -
Use of Patient Support Program Data for Real-World Evidence Generation: Opportunities and Pitfalls Illustrated in a Case Study Assessing Trastuzumab Deruxtecan Among Patients With Breast Cancer
Mar 10, 2025, 14:00 PM -
Outcomes Measured in Multiple Myeloma Trials in the Past 10 Years: Focus on Minimal Residual Disease and Therapy Response
Mar 10, 2025, 14:00 PM -
Long-Term Cost-Effectiveness of a Mobile Health Intervention Delivered by Clinical Pharmacists and Community Health Workers for Type 2 Diabetes Management
Mar 10, 2025, 14:00 PM -
Estimating Epidemiological Estimates of Rare Diseases in Reimbursement Submissions to Canada's Drug Agency: A Comparison of Approaches in the Absence of Local Real-World Data
Mar 10, 2025, 14:00 PM -
Economic Evaluation of Detection, Treatment, and Prevention Interventions for Perinatal Mood and Anxiety Disorders: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Economic Evaluation of Single-Inhaler Extrafine Beclometasone Dipropionate/formoterol fumarate/glycopyrronium (Trimbow®) in Adult Patients with Uncontrolled Asthma in Mexico
Mar 10, 2025, 14:00 PM -
Moving Beyond Partitioned Survival Models in Oncology Submissions: Incorporation of Canada's Drug Agency Guidance on Model Structure
Mar 10, 2025, 14:00 PM -
Measuring the Spillover Effect of Cancer on Family Members' Health: A US-Based Empirical Analysis
Mar 10, 2025, 14:00 PM -
Effectiveness of Digital Care Platforms for Cancer Patients: A Systematic Review and Meta-Analysis
Mar 10, 2025, 14:00 PM -
Budget Analysis of the Implementation of Biosimilars in a Large Private Health Insurance Company in Southern Brazil
Mar 10, 2025, 14:00 PM -
Real-World Evidence in FDA and EMA Regulatory Reviews: Insights on Its Role in Submission Packages and Approvals
Mar 10, 2025, 14:00 PM -
Coverage Gaps: Do U.S. Commercial Health Plans Have Concordant Alzheimer's Disease Therapy & Testing Policies?
Mar 10, 2025, 14:00 PM -
Do Framing and Attribute Number Influence Choice Consistency in a Preference-Based Value Assessment of Equity and Efficiency?
Mar 10, 2025, 14:00 PM -
Is the Assumption of Treatment Waning Applied Consistently Across Canada’s Drug Agency Reimbursement Reviews? Reviewing Pharmacoeconomic Assessments of Disease Modifying Therapies for the Treatment of Multiple Sclerosis
Mar 10, 2025, 14:00 PM -
DAGDraw: A Responsive and Modern Directed Acyclic Graph Drawing Tool for Causal Inference and Transportability Analysis
Mar 10, 2025, 14:00 PM
